|
Real-time Estimate
Cboe BZX
19:53:46 30/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 234.11 USD | +0.76% |
|
-0.73% | +37.16% |
| 01:57pm | Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target | MT |
| 09-22 | Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on | RE |
| Market Cap | 15.08B 13.31B 12.59B 11.42B 21.41B 1,447B 21.62B 151B 58.23B 739B 56.64B 55.4B 2,378B | P/E 2026 * |
16x | P/E 2027 * | 14.1x |
|---|---|---|---|---|---|
| Enterprise Value | 16.92B 14.93B 14.13B 12.81B 24.02B 1,624B 24.26B 169B 65.32B 829B 63.53B 62.15B 2,668B | EV / Sales 2026 * |
3.59x | EV / Sales 2027 * | 2.96x |
| Free-Float |
96.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| JAZZ | Delayed | |
CBOE
| JAZZ | Real-time | |
|
Tradegate
| J7Z | Real-time | |
|
Deutsche Boerse AG
| J7Z | Delayed | |
|
Börse Stuttgart
| J7Z | Delayed | |
|
Boerse Muenchen
| J7Z | Real-time | |
|
Berne S.E.
| J7Z | End-of-day quote | |
|
Borsa Italiana
| 1JAZZ | End-of-day quote | |
|
Xetra
| J7Z | Delayed |
Last Transcript: Jazz Pharmaceuticals plc
| 1 day | +0.71% | ||
| 1 week | -0.73% | ||
| Current month | -6.99% | ||
| 1 month | -6.99% | ||
| 3 months | -3.24% | ||
| 6 months | +27.31% | ||
| Current year | +37.16% |
| 1 week | 229.16 |  | 239.12 |
| 1 month | 229.16 | | 252.72 |
| Current year | 156.95 | | 266.38 |
| 1 year | 128.8 | | 266.38 |
| 3 years | 95.49 | | 266.38 |
| 5 years | 95.49 | | 266.38 |
| 10 years | 86.88 | | 266.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Renée Galá
CEO | Chief Executive Officer | 54 | 11/08/2025 |
Philip Johnson
DFI | Director of Finance/CFO | 62 | 01/03/2024 |
Mary Henderson
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/08/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Cozadd
CHM | Chairman | 62 | 01/03/2003 |
Seamus Mulligan
BRD | Director/Board Member | 65 | 18/01/2012 |
Rick Winningham
BRD | Director/Board Member | 66 | 01/01/2010 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/09/26 | Sell | General Counsel | -1,200 | 0.0018% | ||
| 08/09/26 | Tax | Chief Executive Officer | -3,967 | 0.0061% | ||
| 08/09/26 | Tax | Chief Technology Officer | -1,427 | 0.0022% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.76% | -0.73% | +76.91% | +82.55% | 15.08B | |
| +0.40% | +3.61% | +56.29% | +121.53% | 1,056B | |
| +0.07% | -0.50% | +44.44% | +72.62% | 645B | |
| +0.30% | -0.54% | +13.86% | +77.83% | 465B | |
| -1.58% | -0.83% | +74.97% | +43.20% | 368B | |
| -0.06% | -3.88% | +34.32% | +40.74% | 335B | |
| -0.79% | +2.01% | +19.82% | +28.48% | 275B | |
| -1.19% | -1.21% | +9.82% | +12.15% | 255B | |
| +0.20% | +4.37% | +50.19% | +59.15% | 229B | |
| -0.29% | -0.58% | +35.58% | +103.09% | 188B | |
| Average | -0.16% | -0.23% | +41.62% | +64.13% | 383.09B | |
| Weighted average by Cap. | -0.08% | +0.29% | +42.01% | +74.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.72B 4.16B 3.94B 3.57B 6.7B 453B 6.76B 47.25B 18.21B 231B 17.71B 17.33B 744B | 4.99B 4.41B 4.17B 3.78B 7.09B 479B 7.16B 50.02B 19.28B 245B 18.75B 18.34B 787B |
| Net income | 1B 887M 839M 761M 1.43B 96.43B 1.44B 10.07B 3.88B 49.24B 3.77B 3.69B 158B | 1.14B 1.01B 953M 865M 1.62B 110B 1.64B 11.44B 4.41B 55.94B 4.29B 4.19B 180B |
| Net Debt | 1.84B 1.62B 1.53B 1.39B 2.61B 176B 2.63B 18.4B 7.09B 90.01B 6.9B 6.75B 290B | -277M -245M -232M -210M -394M -26.62B -398M -2.78B -1.07B -13.59B -1.04B -1.02B -43.75B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/09/26 | $233.20 | +0.36% | 222,321 |
| 29/09/26 | $232.35 | -2.49% | 777,839 |
| 28/09/26 | $238.28 | +0.14% | 788,284 |
| 25/09/26 | $237.95 | +0.71% | 1,129,594 |
| 24/09/26 | $236.28 | +0.60% | 551,318 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- JAZZ Stock
Select your edition
All financial news and data tailored to specific country editions
